Aspirin in primary and secondary prevention of cardiovascular diseases: Recommendations based on trials

Aspirin has been recommended by various authorities for primary and secondary prevention of cardiovascular disease (CVD). This review aims to analyse the evidence base of these recommendations to gain insight into their merits and limitations. Use of aspirin for secondary prevention has a more convincing case however in light of recent guidelines; aspirin’s role in primary prevention is also being constantly evaluated and revised. Initial assessment of risk of CVD and bleeding risk is imperative for effectiveness of its role in primary prevention. Evidence also suggests that gender difference exist and females derive more benefit in terms of stroke prevention whereas males get benefit from decreased risk of myocardial infarction. Other high risk populations such as diabetics, stable angina, and asymptomatic coronary artery disease patients also have an evidence base for aspirin recommendation as stated respective guidelines.